Dataset Information

Quantification of internal dosimetry in PET patients II: Individualized Monte Carlo-based dosimetry for [18F]fluorocholine PET.

ABSTRACT:

Purpose

To obtain individualized internal doses with a Monte Carlo (MC) method in patients undergoing diagnostic [18F]FCH-PET studies and to compare such doses with the MIRD method calculations.

Methods

A patient cohort of 17 males were imaged after intravenous administration of a mean [18F]FCH activity of 244.3 MBq. The resulting PET/CT images were processed in order to generate individualized input source and geometry files for dose computation with the MC tool GATE. The resulting dose estimates were studied and compared to the MIRD method with two different computational phantoms. Mass correction of the S-factors was applied when possible. Potential sources of uncertainty were closely examined: the effect of partial body images, urinary bladder emptying, and biokinetic modeling.

Results

Large differences in doses between our methodology and the MIRD method were found, generally in the range ±25%, and up to ±120% for some cases. The mass scaling showed improvements, especially for non-walled and high-uptake tissues. Simulations of the urinary bladder emptying showed negligible effects on doses to other organs, with the exception of the prostate. Dosimetry based on partial PET/CT images (excluding the legs) resulted in an overestimation of mean doses to bone, skin, and remaining tissues, and minor differences in other organs/tissues. Estimated uncertainties associated with the biokinetics of FCH introduce variations of cumulated activities in the range of ±10% in the high-uptake organs.

Conclusions

The MC methodology allows for a higher degree of dosimetry individualization than the MIRD methodology, which in some cases leads to important differences in dose values. Dosimetry of FCH-PET based on a single partial PET study seems viable due to the particular biokinetics of FCH, even though some correction factors may need to be applied to estimate mean skin/bone doses.

SUBMITTER: Neira S

PROVIDER: S-EPMC9291792 | biostudies-literature |

REPOSITORIES: biostudies-literature

ACCESS DATA

Similar Datasets

Project description:Mesh-type and voxel-based computational phantoms comprise the current state of the art for internal dose assessment via Monte Carlo simulations but excel in different aspects, with mesh-type phantoms offering advantages over their voxel counterparts in terms of their flexibility and realistic representation of detailed patient- or subject-specific anatomy. We have developed PARaDIM (pronounced "paradigm": Particle and Heavy Ion Transport Code System-Based Application for Radionuclide Dosimetry in Meshes), a freeware application for implementing tetrahedral mesh-type phantoms in absorbed dose calculations. It considers all medically relevant radionuclides, including α, β, γ, positron, and Auger/conversion electron emitters, and handles calculation of mean dose to individual regions, as well as 3-dimensional dose distributions for visualization and analysis in a variety of medical imaging software. This work describes the development of PARaDIM, documents the measures taken to test and validate its performance, and presents examples of its uses. Methods: Human, small-animal, and cell-level dose calculations were performed with PARaDIM and the results compared with those of widely accepted dosimetry programs and literature data. Several tetrahedral phantoms were developed or adapted using computer-aided modeling techniques for these comparisons. Results: For human dose calculations, agreement of PARaDIM with OLINDA 2.0 was good-within 10%-20% for most organs-despite geometric differences among the phantoms tested. Agreement with MIRDcell for cell-level S value calculations was within 5% in most cases. Conclusion: PARaDIM extends the use of Monte Carlo dose calculations to the broader community in nuclear medicine by providing a user-friendly graphical user interface for calculation setup and execution. PARaDIM leverages the enhanced anatomic realism provided by advanced computational reference phantoms or bespoke image-derived phantoms to enable improved assessments of radiation doses in a variety of radiopharmaceutical use cases, research, and preclinical development. PARaDIM can be downloaded freely at www.paradim-dose.org.

Project description:PurposeTo validate Monte Carlo (MC)-based breast dosimetry estimations using both a homogeneous and a 3D anthropomorphic breast phantom under polyenergetic irradiation for internal breast dosimetry purposes.MethodsExperimental measurements were performed with a clinical digital mammography system (Mammomat Inspiration, Siemens Healthcare), using the x-ray spectrum selected by the automatic exposure control and a tube current-exposure time product of 360 mAs. A homogeneous 50% glandular breast phantom and a 3D anthropomorphic breast phantom were used to investigate the dose at different depths (range 0-4 cm with 1 cm steps) for the homogeneous case and at a depth of 2.25 cm for the anthropomorphic case. Local dose deposition was measured using thermoluminescent dosimeters (TLD), metal oxide semiconductor field-effect transistor dosimeters (MOSFET), and GafChromic™ films. A Geant4-based MC simulation was modified to match the clinical experimental setup. Thirty sensitive volumes (3.2 × 3.2 × 0.38 mm3 ) on the axial-phantom plane were included at each depth in the simulation to characterize the internal dose variation and compare it to the experimental TLD and MOSFET measurements. The experimental 2D dose maps obtained with the GafChromic™ films were compared to the simulated 2D dose distributions.ResultsDue to the energy dependence of the dosimeters and due to x-ray beam hardening, dosimeters based on these three technologies have to be calibrated at each depth of the phantom. As expected, the dose was found to decrease with increasing phantom depth, with the reduction being ~93% after 4 cm for the homogeneous breast phantom. The 2D dose map showed nonuniformities in the dose distribution in the axial plane of the phantom. The mean combined standard uncertainty increased with phantom depth by up to 5.3% for TLD, 6.3% for MOSFET, and 9.6% for GafChromic™ film. In the case of a heterogeneous phantom, the dosimeters are able to detect local dose gradient variations. In particular, GafChromic™ film showed local dose variations of about 46% at the boundaries of two materials.ConclusionsResults showed a good agreement between experimental measurements (with TLD and MOSFET) and MC data for both homogeneous and anthropomorphic breast phantoms. Larger discrepancies are found when comparing the GafChromic™ dose values to the MC results due to the inherent less precise nature of the former. MC validations in a heterogeneous background at the level of local dose deposition and in absolute terms play a fundamental role in the development of an accurate method to estimate radiation dose. The potential introduction of a breast dosimetry model involving a nonhomogeneous glandular/adipose tissue composition makes the validation of internal dose distributions estimates crucial.

Project description:BackgroundProton pencil beam (PB) dose calculation algorithms have limited accuracy within heterogeneous tissues of lung cancer patients, which may be addressed by modern commercial Monte Carlo (MC) algorithms. We investigated clinical pencil beam scanning (PBS) dose differences between PB and MC-based treatment planning for lung cancer patients.MethodsWith IRB approval, a comparative dosimetric analysis between RayStation MC and PB dose engines was performed on ten patient plans. PBS gantry plans were generated using single-field optimization technique to maintain target coverage under range and setup uncertainties. Dose differences between PB-optimized (PBopt), MC-recalculated (MCrecalc), and MC-optimized (MCopt) plans were recorded for the following region-of-interest metrics: clinical target volume (CTV) V95, CTV homogeneity index (HI), total lung V20, total lung VRX (relative lung volume receiving prescribed dose or higher), and global maximum dose. The impact of PB-based and MC-based planning on robustness to systematic perturbation of range (±3% density) and setup (±3 mm isotropic) was assessed. Pairwise differences in dose parameters were evaluated through non-parametric Friedman and Wilcoxon sign-rank testing.ResultsIn this ten-patient sample, CTV V95 decreased significantly from 99-100% for PBopt to 77-94% for MCrecalc and recovered to 99-100% for MCopt (P<10-5). The median CTV HI (D95/D5) decreased from 0.98 for PBopt to 0.91 for MCrecalc and increased to 0.95 for MCopt (P<10-3). CTV D95 robustness to range and setup errors improved under MCopt (ΔD95 =-1%) compared to MCrecalc (ΔD95 =-6%, P=0.006). No changes in lung dosimetry were observed for large volumes receiving low to intermediate doses (e.g., V20), while differences between PB-based and MC-based planning were noted for small volumes receiving high doses (e.g., VRX). Global maximum patient dose increased from 106% for PBopt to 109% for MCrecalc and 112% for MCopt (P<10-3).ConclusionsMC dosimetry revealed a reduction in target dose coverage under PB-based planning that was regained under MC-based planning along with improved plan robustness. MC-based optimization and dose calculation should be integrated into clinical planning workflows of lung cancer patients receiving actively scanned proton therapy.

Project description:IntroductionThe use of high-dose-rate brachytherapy is currently a widespread practice worldwide. The most common isotope source is 192Ir, but 60Co is also becoming available for HDR. One of main advantages of 60Co compared to 192Ir is the economic and practical benefit because of its longer half-live, which is 5.27 years. Recently, Eckert & Ziegler BEBIG, Germany, introduced a new afterloading brachytherapy machine (MultiSource®); it has the option to use either the 60Co or 192Ir HDR source. The source for the Monte Carlo calculations is the new 60Co source (model Co0.A86), which is referred to as the new BEBIG 60Co HDR source and is a modified version of the 60Co source (model GK60M21), which is also from BEBIG.Objective and methodsThe purpose of this work is to obtain the dosimetry parameters in accordance with the AAPM TG-43U1 formalism with Monte Carlo calculations regarding the BEBIG 60Co high-dose-rate brachytherapy to investigate the required treatment-planning parameters. The geometric design and material details of the source was provided by the manufacturer and was used to define the Monte Carlo geometry. To validate the source geometry, a few dosimetry parameters had to be calculated according to the AAPM TG-43U1 formalism. The dosimetry studies included the calculation of the air kerma strength Sk, collision kerma in water along the transverse axis with an unbounded phantom, dose rate constant and radial dose function. The Monte Carlo code system that was used was EGSnrc with a new cavity code, which is a part of EGS++ that allows calculating the radial dose function around the source. The spectrum to simulate 60Co was composed of two photon energies, 1.17 and 1.33 MeV. Only the gamma part of the spectrum was used; the contribution of the electrons to the dose is negligible because of the full absorption by the stainless-steel wall around the metallic 60Co. The XCOM photon cross-section library was used in subsequent simulations, and the photoelectric effect, pair production, Rayleigh scattering and bound Compton scattering were included in the simulation. Variance reduction techniques were used to speed up the calculation and to considerably reduce the computer time. The cut-off energy was 10 keV for electrons and photons. To obtain the dose rate distributions of the source in an unbounded liquid water phantom, the source was immersed at the center of a cube phantom of 100 cm3. The liquid water density was 0.998 g/cm3, and photon histories of up to 1010 were used to obtain the results with a standard deviation of less than 0.5% (k = 1). The obtained dose rate constant for the BEBIG 60Co source was 1.108±0.001 cGyh-1U-1, which is consistent with the values in the literature. The radial dose functions were compared with the values of the consensus data set in the literature, and they are consistent with the published data for this energy range.

Project description:Although there are many works on evaluating dose calculations of the anisotropic analytical algorithm (AAA) using various homogeneous and heterogeneous phantoms, related work concerning dosimetry due to tangential photon beam is lacking. In this study, dosimetry predicted by the AAA and collapsed cone convolution (CCC) algorithm was evaluated using the tangential photon beam and phantom geometry. The photon beams of 6 and 15 MV with field sizes of 4 × 4 (or 7 × 7), 10 × 10 and 20 × 20 cm², produced by a Varian 21 EX linear accelerator, were used to test performances of the AAA and CCC using Monte Carlo (MC) simulation (EGSnrc-based code) as a benchmark. Horizontal dose profiles at different depths, phantom skin profiles (i.e., vertical dose profiles at a distance of 2 mm from the phantom lateral surface), gamma dose distributions, and dose-volume histograms (DVHs) of skin slab were determined. For dose profiles at different depths, the CCC agreed better with doses in the air-phantom region, while both the AAA and CCC agreed well with doses in the penumbra region, when compared to the MC. Gamma evaluations between the AAA/CCC and MC showed that deviations of 2D dose distribution occurred in both beam edges in the phantom and air-phantom interface. Moreover, the gamma dose deviation is less significant in the air-phantom interface than the penumbra. DVHs of skin slab showed that both the AAA and CCC underestimated the width of the dose drop-off region for both the 6 and 15 MV photon beams. When the gantry angle was 0°, it was found that both the AAA and CCC overestimated doses in the phantom skin profiles compared to the MC, with various photon beam energies and field sizes. The mean dose differences with doses normalized to the prescription point for the AAA and CCC were respectively: 7.6% ± 2.6% and 2.1% ± 1.3% for a 10 × 10 cm2 field, 6 MV; 16.3%± 2.1% and 6.7% ± 2.1% for a 20 × 20 cm2 field, 6 MV; 5.5% ± 1.2% and 1.7% ± 1.4% for a 10 × 10 cm2, 15 MV; 18.0% ± 1.3% and 8.3% ± 1.8% for a 20 × 20 cm², 15 MV. However, underestimations of doses in the phantom skin profile were found with small fields of 4 × 4 and 7 × 7 cm² for the 6 and 15 MV photon beams, respectively, when the gantry was turned 5° anticlockwise. As surface dose with tangential photon beam geometry is important in some radiation treatment sites such as breast, chest wall and sarcoma, it is found that neither of the treatment planning system algorithms can predict the dose well at depths shallower than 2 mm. The dosimetry data and beam and phantom geometry in this study provide a better knowledge of a dose calculation algorithm in tangential-like irradiation.

Project description:PURPOSE:Beta-secretase 1 (BACE1) enzyme is implicated in the pathophysiology of Alzheimer's disease. [18F]PF-06684511 is a positron emission tomography (PET) radioligand for imaging BACE1. Despite favorable brain kinetic properties, the effective dose (ED) of [18F]PF-06684511 estimated in non-human primates was relatively high. This study was therefore designed to evaluate the whole-body distribution, dosimetry, quantification, and test-retest reliability of imaging brain BACE1 with [18F]PF-06684511 in healthy volunteers. METHODS:Five subjects were studied for the dosimetry study. Whole-body PET was performed for 366 min with 4 PET-CT sessions. Estimates of the absorbed radiation dose were calculated using the male adult model. Eight subjects participated in the test-retest study. Brain PET measurements were conducted for 123 min with an interval of 5 to 19 days between test and retest conditions. The total distribution volume (VT) was estimated with one-tissue (1T), two-tissue (2T), compartment model (CM), and graphical analysis. Test-retest variability (TRV) and intraclass correlation coefficient (ICC) of VT were calculated as reliability measures. RESULTS:In the dosimetry study, the highest uptake was found in the liver (25.2?±?2.3 %ID at 0.5 h) and the largest dose was observed in the pancreas (92.9?±?52.2 ?Sv/MBq). The calculated ED was 24.7?±?0.8 ?Sv/MBq. In the test-retest study, 2TCM described the time-activity curves well. VT (2TCM) was the highest in the anterior cingulate cortex (6.28?±?1.09 and 6.85?±?0.81) and the lowest in the cerebellum (4.23?±?0.88 and 4.20?±?0.75). Mean TRV and ICC of VT (2TCM) were 16.5% (12.4-20.5%) and 0.496 (0.291-0.644). CONCLUSION:The ED of [18F]PF-06684511 was similar to other 18F radioligands, allowing repeated PET measurements. 2TCM was the most appropriate quantification method. TRV of VT was similar to other radioligands without a reference region, albeit with lower ICC. These data indicated that [18F]PF-06684511 is a suitable radioligand to measure BACE1 level in the human brain. TRIAL REGISTRATION:EudraCT 2016-001110-19 (registered 2016-08-08).

Project description:A model based on a specific phantom, called QuAArC, has been designed for the evaluation of planning and verification systems of complex radiotherapy treatments, such as volumetric modulated arc therapy (VMAT). This model uses the high accuracy provided by the Monte Carlo (MC) simulation of log files and allows the experimental feedback from the high spatial resolution of films hosted in QuAArC. This cylindrical phantom was specifically designed to host films rolled at different radial distances able to take into account the entrance fluence and the 3D dose distribution. Ionization chamber measurements are also included in the feedback process for absolute dose considerations. In this way, automated MC simulation of treatment log files is implemented to calculate the actual delivery geometries, while the monitor units are experimentally adjusted to reconstruct the dose-volume histogram (DVH) on the patient CT. Prostate and head and neck clinical cases, previously planned with Monaco and Pinnacle treatment planning systems and verified with two different commercial systems (Delta4 and COMPASS), were selected in order to test operational feasibility of the proposed model. The proper operation of the feedback procedure was proved through the achieved high agreement between reconstructed dose distributions and the film measurements (global gamma passing rates > 90% for the 2%/2 mm criteria). The necessary discretization level of the log file for dose calculation and the potential mismatching between calculated control points and detection grid in the verification process were discussed. Besides the effect of dose calculation accuracy of the analytic algorithm implemented in treatment planning systems for a dynamic technique, it was discussed the importance of the detection density level and its location in VMAT specific phantom to obtain a more reliable DVH in the patient CT. The proposed model also showed enough robustness and efficiency to be considered as a pre-treatment VMAT verification system.